Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...
Now, scientists at McGill University may have found a way to ease that burden. They’ve developed a light-activated ...
A McGill University research team has developed a painless, automated way to deliver in vitro fertilization (IVF) hormones ...
Foresee Pharmaceuticals has shown that a long-acting version of its injectable prostate cancer med Camcevi can help patients ...
The 8-year overall survival rate was 78.9% with enzalutamide-leuprolide and 69.5% with leuprolide alone. Treatment with enzalutamide plus leuprolide reduces the risk of death by more than 40% in ...
Hosted on MSN
Enzalutamide + Leuprolide Boosts Overall Survival for Prostate Cancer With High Recurrence Risk
THURSDAY, Oct. 23, 2025 (HealthDay News) -- The combination of enzalutamide and leuprolide significantly improves overall survival among patients with prostate cancer and a high risk for biochemical ...
A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer. Adding the drug enzalutamide to standard hormone therapy reduced the risk of ...
(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination with leuprolide and ...
Those with prostate cancer that returns after surgery or radiation—and typically face a high risk of the disease spreading and death—could benefit from a new drug combination. A Cedars-Sinai Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback